Cited 34 times in
Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2018-01-23T05:53:16Z | - |
dc.date.available | 2018-01-23T05:53:16Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/155778 | - |
dc.description.abstract | BACKGROUND: Dacomitinib, an irreversible panHER inhibitor, shows significant preclinical antitumor activity in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). The aim of this study was to evaluate the clinical activity of dacomitinib and discover potential biomarkers in HER2-positive GC patients. METHODS: We enrolled previously treated advanced HER2-positive GC [HER2 FISH (+) or HER2 IHC 3+] patients. The patients received dacomitinib 45 mg once daily. RESULTS: A total of 27 patients were enrolled. The number of prior chemotherapy regimens was 1 in 7 patients (26 %), 2 in 9 patients (33 %), and more than 2 in 11 patients (41 %). Seven patients had received prior anti-HER2 therapy. The 4-month progression-free survival (PFS) rate was 22.2 % and median PFS was 2.1 months (95 % CI, 2.3-3.4) There were 2 partial response (PRs) and 9 stable disease (SDs), resulting in 7.4 % (95 % CI, 0-17.5 %) of response rate (RR) and 40.7 % (95 % CI, 21.9-59.6 %) of disease control rate (DCR). Eleven patients (41 %) showed some degree of tumor shrinkage. Overall survival was 7.1 months (95 % CI, 4.4-9.8). The most common toxicities were skin rash, diarrhea, and fatigue, most of which were grade 1 or 2. The Ctrough of dacomitinib was lower in gastrectomy patients than nongastrectomy patients. Higher serum levels of HER2 extracellular domain (ECD) and lower levels of soluble E-cadherin (sECAD) correlated with higher dacomitinib activity. CONCLUSIONS: Dacomitinib functions as a single agent in HER2-positive GC patients with a tolerable safety profile. HER2 ECD and sECAD have the potential to be biomarkers for patient selection in a panHER inhibition strategy for HER2-positive GC. (ClinicalTrials.gov: NCT01152853). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | Kewn-Wook Lee | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.contributor.googleauthor | Won Ki Kang | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Jin Won Kim | - |
dc.contributor.googleauthor | Yung-Jue Bang | - |
dc.identifier.doi | 10.1007/s10120-015-0567-z | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J00916 | - |
dc.identifier.eissn | 1436-3305 | - |
dc.identifier.pmid | 26581547 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s10120-015-0567-z | - |
dc.contributor.alternativeName | Cho, Jae Yong | - |
dc.contributor.affiliatedAuthor | Cho, Jae Yong | - |
dc.citation.volume | 19 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 1095 | - |
dc.citation.endPage | 1103 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, Vol.19(4) : 1095-1103, 2016 | - |
dc.identifier.rimsid | 48811 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.